Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $35.00 Price Target at TD Cowen

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price objective raised by TD Cowen from $30.00 to $35.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. HC Wainwright raised their target price on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday. The Goldman Sachs Group boosted their price target on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Zacks Research cut Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Finally, Needham & Company LLC lifted their price objective on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $31.67.

Arcutis Biotherapeutics Stock Up 5.8%

Arcutis Biotherapeutics stock opened at $28.57 on Thursday. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of -204.06 and a beta of 1.70. Arcutis Biotherapeutics has a 52-week low of $11.86 and a 52-week high of $31.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. The firm has a 50 day moving average price of $27.26 and a two-hundred day moving average price of $23.71.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.10. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 11.01%. The company had revenue of $129.50 million during the quarter, compared to analysts’ expectations of $110.79 million. Equities analysts predict that Arcutis Biotherapeutics will post -1.33 EPS for the current year.

Insider Transactions at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.05, for a total transaction of $250,500.00. Following the completion of the sale, the director owned 59,744 shares in the company, valued at $1,496,587.20. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Patrick Burnett sold 9,794 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $25.81, for a total value of $252,783.14. Following the completion of the transaction, the insider owned 80,651 shares in the company, valued at approximately $2,081,602.31. This represents a 10.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 124,656 shares of company stock valued at $3,312,365. Company insiders own 9.40% of the company’s stock.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its position in Arcutis Biotherapeutics by 21.4% in the 1st quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock valued at $3,882,000 after acquiring an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Arcutis Biotherapeutics by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after purchasing an additional 2,063 shares in the last quarter. AlphaQuest LLC raised its stake in shares of Arcutis Biotherapeutics by 101.1% in the second quarter. AlphaQuest LLC now owns 11,921 shares of the company’s stock worth $167,000 after purchasing an additional 5,994 shares during the last quarter. Corton Capital Inc. bought a new position in shares of Arcutis Biotherapeutics in the second quarter valued at approximately $238,000. Finally, Atlas Wealth LLC purchased a new position in shares of Arcutis Biotherapeutics during the second quarter valued at approximately $138,000.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Reported a robust Q4: ZORYVE product revenue of $127.5M (+84% YoY) and full‑year ZORYVE sales of $372.1M (+123% YoY); company raised 2026 net product sales guidance to $480–$495M — a clear driver of upward momentum. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Beat EPS and revenue estimates: Q4 GAAP EPS $0.13 vs. consensus $0.03 and revenue ~$129.5M vs. $110.8M expected — the earnings beat and recurring revenue growth support a re-rating. ARQT Earnings Report
• Positive Sentiment: Clinical and regulatory catalyst: positive topline data in a Phase 2 infant trial for ZORYVE with an sNDA submission expected in Q2 2026 — potential label expansion that could meaningfully grow addressable market. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst upgrades: Needham raised its PT to $36 (buy) and TD Cowen raised its PT to $35 (buy), both implying >20% upside from current levels — these broker actions can drive buying interest. Needham Price Target Raise
• Positive Sentiment: Operational improvements: company produced positive operating cash flow in Q4 and expects to maintain positive operating cash flow quarterly going forward; also expanding dermatology sales and targeting primary care/pediatrics — supports sustainable commercialization. Business Update and Guidance
• Neutral Sentiment: Wall‑street commentary and analysis: bullish writeups (Seeking Alpha) highlight ZORYVE dominance and pipeline catalysts but note valuation is elevated (~9x forward EV/sales). Seeking Alpha Bull Case
• Neutral Sentiment: Marketing/awareness initiatives: consumer awareness campaign (celebrity partnership) may help demand over time but is not an immediate revenue driver. Marketing Campaign
• Neutral Sentiment: Short interest data reported is internally inconsistent (zeros/NaN) and provides no actionable signal. (Ignore until clearer filings are available.)
• Negative Sentiment: Profitability metrics remain mixed: company still showed negative net margin and negative ROE in some reports, and some analysts project a net loss (consensus -1.33 EPS for the year) — these fundamentals temper the upside and could limit multiple expansion if growth slows. ARQT Stock Summary

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.